Lauková L, et al. - Experts described the impacts of biological disease-modifying antirheumatic drugs (bDMARDs)s on plasma extracellular DNA (ecDNA) and its nuclear (nDNA) and mitochondrial (mtDNA) fractions in patients with rheumatoid arthritis (RA). Plasma ecDNA of both nuclear and mitochondrial origin was seen to decrease with the treatment with bDMARDs. Compared to the dynamics of standard clinical markers, the dynamics of ecDNA was slower. Hence, they noted the likeliness of it to be not useful for monitoring of the disease progress, at least for RA.